Literature DB >> 19639323

Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1.

Ana Karina Ferraz-Chaoui1, Ajax Mercês Atta, Maria Luiza Sousa Atta, Bernardo Galvão-Castro, Mittermayer B Santiago.   

Abstract

Human T cell lymphotropic virus type 1 (HTLV-1) is endemic in many regions of the world, including Brazil, and has been associated to several immunological manifestations such as arthritis, uveitis, dermatitis and Sjögren's syndrome. This study was intended to evaluate the frequency of autoantibodies in patients infected with HTLV-1 and manifesting keratoconjunctivitis sicca (KCS). HTLV-1 patients with KCS, enrolled in a reference ambulatory of the city of Salvador, were tested for autoantibodies such as antinuclear antibodies, rheumatoid factor, anti-SSA/Ro and anti-SSB/La. Two comparison groups were also included: (a) HTLV-1 patients without KCS and (b) seronegative patients with KCS. Correlation of proviral load (PVL) in HTLV-1 patients with presence or absence of KCS was also assessed. No autoantibodies were detected in HTLV-1 patients with KCS. The PVL of HTLV-1 patients was higher in patients with KCS without other clinical manifestations customarily associated to HTLV-1. In conclusion, in this study, no changes were observed in humoral immunity concerning production of certain autoantibodies in HTLV-1-infected patients with KCS, which suggests that other mechanisms may be involved in the pathogenesis of this manifestation. Additionally, PVL may be a marker of KCS development in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639323     DOI: 10.1007/s00296-009-1066-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  30 in total

1.  Primary Sjögren's syndrome with antibodies to HTLV-I: clinical and laboratory features.

Authors:  K Eguchi; N Matsuoka; H Ida; M Nakashima; M Sakai; S Sakito; A Kawakami; K Terada; H Shimada; Y Kawabe
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  P A Montanheiro; P A Montanheito; A C Penalva de Oliveira; M P Posada-Vergara; A C Milagres; C Tauil; P E Marchiori; A J S Duarte; J Casseb
Journal:  Braz J Med Biol Res       Date:  2005-10-26       Impact factor: 2.590

3.  Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study.

Authors:  B Galvão-Castro; L Loures; L G Rodriques; A Sereno; O C Ferreira Júnior; L G Franco; M Muller; D A Sampaio; A Santana; L M Passos; F Proietti
Journal:  Transfusion       Date:  1997-02       Impact factor: 3.157

4.  HTLV-1 and polymyositis in Jamaica.

Authors:  O S Morgan; P Rodgers-Johnson; C Mora; G Char
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

5.  New corneal findings in human T-cell lymphotrophic virus type 1 infection.

Authors:  R R Buggage; G A Levy-Clarke; J A Smith
Journal:  Am J Ophthalmol       Date:  2001-03       Impact factor: 5.258

6.  Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice.

Authors:  J E Green; S H Hinrichs; J Vogel; G Jay
Journal:  Nature       Date:  1989-09-07       Impact factor: 49.962

7.  Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier.

Authors:  S Ijichi; T Matsuda; I Maruyama; T Izumihara; K Kojima; T Niimura; Y Maruyama; S Sonoda; A Yoshida; M Osame
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

8.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

9.  Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome.

Authors:  K Terada; S Katamine; K Eguchi; R Moriuchi; M Kita; H Shimada; I Yamashita; K Iwata; Y Tsuji; S Nagataki
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

10.  [Salivary and lacrymal gland disorders and HTLV-1 infection].

Authors:  S P Giozza; S B Santos; M Martinelli; M A Porto; A L Muniz; E M Carvalho
Journal:  Rev Stomatol Chir Maxillofac       Date:  2008-03-28
View more
  5 in total

1.  Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.

Authors:  Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby
Journal:  J Clin Virol       Date:  2011-03-08       Impact factor: 3.168

2.  Association of Sicca Syndrome with Proviral Load and Proinflammatory Cytokines in HTLV-1 Infection.

Authors:  Clara Mônica Lima; Silvane Santos; Adriana Dourado; Natália B Carvalho; Valéria Bittencourt; Marcus Miranda Lessa; Isadora Siqueira; Edgar M Carvalho
Journal:  J Immunol Res       Date:  2016-01-19       Impact factor: 4.818

3.  Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients.

Authors:  Rilma F S Santos; Gildásio C Conceição; Márcia S Martins; Angiolina Kraychete; Maria A C Penalva; Edgar M Carvalho; Antonio Alberto Lopes; Paulo Novis Rocha
Journal:  BMC Nephrol       Date:  2017-02-15       Impact factor: 2.388

4.  Evaluation of the cervicovaginal environment in asymptomatic Human T-cell lymphotropic virus type 1 infected women.

Authors:  Alisson de Aquino Firmino; Adenilda Lima Lopes Martins; Luana Leandro Gois; Taiane Silva Paixão; Everton da Silva Batista; Bernardo Galvão-Castro; Maria Fernanda Rios Grassi
Journal:  Braz J Infect Dis       Date:  2019-03-06       Impact factor: 3.257

5.  Revisiting Keratoconjunctivitis sicca associated with Human T-Cell Lymphotropic Virus Type 1: prevalence, clinical aspects and proviral load.

Authors:  Regina Helena Rathsam-Pinheiro; Ney Boa-Sorte; Maria Fernanda Rios Grassi; Úrsula Cury Copello; Karla Tayrine Silva Guimarães Rios; Thessika Araújo; Bernardo Galvão-Castro
Journal:  Braz J Infect Dis       Date:  2019-05-03       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.